What's the maximum dose of semaglutide for weight loss?

What does the full dosing schedule look like before you hit the maximum?

Semaglutide for weight loss follows a stepped titration designed primarily to reduce the likelihood of nausea and other gastrointestinal side effects in the early weeks. The journey starts at 0.25mg once weekly, a level that does very little in terms of weight reduction but gives your digestive system time to settle. After roughly four weeks, the prescriber moves you to 0.5mg, then 1.0mg, then 1.7mg, and finally the standard maintenance dose of 2.4mg. That five-rung ladder was the complete picture until early 2026.

The full Wegovy dosing structure now extends beyond 2.4mg. Patients who have been stable on the weekly 2.4mg injection can, subject to clinical review, progress to the 7.2mg maintenance dose. That additional step was initially delivered as three separate 2.4mg pens in a single week, before the MHRA approved a dedicated single-dose 7.2mg pen on 14 April 2026. Each move up the schedule requires a prescriber's sign-off, there is no self-escalation.

The NHS medicines information for semaglutide sets out the general principles of the titration approach and what patients should expect at each stage. A practical checking habit worth building: before each new pen, glance at the printed strength on the cartridge label and confirm it matches what your prescriber said to use next. Takes about ten seconds and catches the occasional dispensing mix-up before it becomes a problem.

How does reaching 7.2mg change the results picture?

The trial evidence behind the 7.2mg approval is meaningful. Clinical data reported around 20.7% average body-weight reduction over 72 weeks at the higher dose, a figure that closes much of the gap between semaglutide and tirzepatide's headline numbers from the SURMOUNT programme. For context, the STEP 1 trial (the pivotal study behind the original 2.4mg licence) recorded roughly 15% average loss over 68 weeks, as published in the New England Journal of Medicine.

That additional five percentage points matters clinically for a significant number of people. Weight loss at this scale can move someone out of the range where certain comorbidities (high blood pressure, dyslipidaemia, sleep apnoea) remain poorly controlled. The 7.2mg option therefore widens the therapeutic ceiling without requiring a switch to a different medicine.

One limit worth knowing: the 7.2mg approval applies specifically to weight management in adults with a BMI of 30 or above. It is not authorised at this strength for the cardiovascular risk-reduction indication that some patients on lower-dose semaglutide are prescribed for. If you are using semaglutide for any reason other than weight management, the maximum dose that applies to you may be different, a conversation for your own prescriber.

Who actually reaches the maximum dose of Wegovy, and when might a prescriber stop before it?

Not every patient progresses to 7.2mg, and that is by design rather than failure. A meaningful proportion of people on semaglutide achieve their clinical goals well before the maximum Wegovy dose, at 1.7mg or 2.4mg, and there is no clinical reason to push higher simply because a higher option exists. NICE guidance on semaglutide (TA875) advises reviewing whether to continue treatment if less than 5% of starting body weight has been lost after six months on the maintenance dose. That same logic applies here: if the medicine is working at a lower level, the dose is not automatically escalated.

Side-effect tolerance also shapes the decision. Gastrointestinal effects (nausea, loose stools, reflux, reduced appetite leading to fatigue) tend to be most pronounced after a dose increase and usually ease within a couple of weeks. Some patients find 2.4mg sits at the edge of what they tolerate comfortably, and moving to 7.2mg would tip the balance. A prescriber who knows your history will weigh that carefully. You can read more about what the maximum dose of semaglutide means in practice and how clinical decisions around it are made.

For anyone considering Wegovy privately, the free consultation at nume is the starting point: a GPhC-registered prescriber reads your full clinical picture the same day, and the dose you begin on (and any later increases) is their call, made safely. If you have questions about the process before starting, our FAQs cover the most common ones.

What about oral semaglutide, does the maximum dose differ?

Yes, and it differs quite substantially in numerical terms. The Wegovy tablet (approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK) uses a completely separate dosing scale: 1.5mg daily, rising through 4mg and 9mg to a maintenance dose of 25mg once daily. The numbers look very different from the injection schedule, but this reflects the biology of oral absorption rather than a stronger medicine. Bioavailability of semaglutide taken by mouth is far lower than by injection, so the tablet strengths are calibrated accordingly.

The 25mg tablet is not interchangeable with 2.4mg injection, they are different formulations targeting a comparable therapeutic effect. Patients already stable on the 2.4mg weekly injection may move to the 25mg tablet directly, subject to prescriber assessment. The oral route removes the need for injections entirely and requires no refrigeration, which some people find considerably more practical. An overview of the broader weight-loss treatment options at nume covers both formulations alongside other licensed medicines. The key point remains consistent across both routes: the maximum dose is the ceiling a prescriber moves you towards if clinically appropriate, not a target to aim for from day one.